BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price target from $144 to $170.